Structural Basis of MERS-CoV Receptor Interactions and Antibody Neutralisations

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Coronaviruses pose a significant global health threat, necessitating broad-spectrum antivirals and vaccines.
• Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen with a high mortality rate (approx. 35%) and pandemic potential.
• Current therapeutic and preventative options against MERS-CoV are limited, with no approved vaccines or antiviral drugs available.

Purpose of the Study:

• To review current progress in antibody research against MERS-CoV infections.
• To discuss MERS-CoV receptor usage and the mechanisms of MERS-CoV-derived neutralizing antibodies (nAbs).
• To provide insights for the development of MERS-CoV specific and next-generation pan-coronavirus vaccines and antivirals.

Main Methods:

• Analysis of MERS-CoV receptor usage.
• Review of existing literature on MERS-CoV antibody research.
• Examination of structural data of spike glycoprotein-antibody complexes to understand cross-reactivity and cross-neutralization mechanisms.

Main Results:

• Neutralizing antibodies (nAbs) are promising candidates for MERS-CoV treatment and prevention.
• Understanding antibody interactions with the MERS-CoV spike glycoprotein is key to developing effective therapies.
• Cross-reactivity and cross-neutralization mechanisms of MERS-CoV nAbs offer potential for broad-spectrum coronavirus therapies.

Conclusions:

• Further research into MERS-CoV nAbs is essential for developing targeted vaccines and antivirals.
• Insights gained from MERS-CoV antibody research can inform the design of next-generation pan-coronavirus vaccines.
• Developing broad-spectrum coronavirus therapies is critical given the increasing threat of viral outbreaks.